Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

ginning at 8 P.M. EDT. Access numbers for this replay are 888-203-1112 (U.S./Canada) and 719-457-0820 (international); participant code 4106309.

Amicus' press releases are available at http://www.amicustherapeutics.com

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease. The Company recently completed Phase I clinical trials of AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

This Press release contains and the accompanying conference call will contain "forward-looking statements" within the meaning of Section 21E of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Examples of such statements include: (i) statements regarding the goals and expected timing of clinical studies, including the effect of the completion of the Phase 2 clinical trial for Amigal for the treatment of Fabry disease, the timing and design of Phase 3 clinical development for Amigal, the Phase 2 clinical trials for Plicera for the treatment of Gaucher disease, the effect of
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 This ... perspectives on nonclinical and clinical safety assessment in ... to guide a path for biosimilar drug development, ... demonstration of biosimilarity with regards to quality, safety ... aspects of biosimilar drug development and registration, development ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory ... One of these latent viruses is the Epstein Barr ... arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory ... the theory, a study found that RA patients have ... , What is Microcompetition? , Dr. Hanan Polansky ...
(Date:1/15/2014)... AudioNotch is the internet's leading ... for the treatment of tinnitus. Patients listen to ... frequency, and over a period of weeks to months, ... Notched Sound Therapy in two forms: Notched Music and ... to release of a new form of Tailor-Made Notched ...
(Date:1/14/2014)... Diego, CA (PRWEB) January 14, 2014 ... solutions based on the products of cells grown ... have entered into an international license agreement with ... Histogen’s proprietary multipotent cell conditioned media (CCM). ... the existing license between Histogen and Suneva Medical, ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... ... of Chronic Wounds, ... focused on improving patient quality of life, today,announced that its ... KFH Novo medical device, a breakthrough medical,technology that enhances the ...
... 11 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ) announced ... 28th Annual Healthcare Conference on Tuesday, March 18, 2008 ... being held at the Boston,Marriot Copley Place., Steve ... Inc., will present an overview of Anadys and its ...
... 11 Nile Therapeutics,Inc. (OTC Bulletin Board: NILT), today ... financial results for 2007 after the market,closes on Thursday, ... and live webcast to discuss these financial results and ... 4:30 p.m. ET, 1:30 p.m. PT,that afternoon., Interested ...
Cached Biology Technology:Kingfisher Healthcare Receives European CE Mark for Next Generation Wound Healing Device 2Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference 2Nile Therapeutics to Announce 2007 Fourth Quarter and Full Year Financial Results on Thursday, March 13, 2008 2
(Date:4/15/2014)... Puerto Rican community is creating a tropical home away ... has caught the attention of scientists. David W. Taylor ... Connecticut) took a close look at the fresh crops ... evidence that gives new meaning to a phrase that ... in the kitchen. , "Culinary preferences tell us a ...
(Date:4/15/2014)... University of Missouri researchers have previously shown that a ... exercise exists. In a new study, Frank Booth, a ... found a potential link between the genetic pre-disposition for ... which mental maturation occurs. , For his study, Booth ... activity or extreme laziness. Booth then put the rats ...
(Date:4/15/2014)... Case Western Reserve University dental researchers have found ... immune cells from the mouth to study how ... inflammation. , By isolating some specialized immune cells ... how they fight diseases in the mouthor reject ... hope to learn more about treating and preventing ...
Breaking Biology News(10 mins):The human food connection: A new study reveals more about our relationship to food 2The human food connection: A new study reveals more about our relationship to food 3Genetic pre-disposition toward exercise and mental development may be linked 2New method isolates immune cells for researchers to study how they ward off oral diseases 2
... been named as one of the 2008 Environmental Scientists ... His half-brother, biologist Jules Blais, is the other winner ... prestigious in the environmental sciences. The prize recognizes the ... Smol is series editor of the Springer ...
... 2 BIO-key International,Inc. (OTC Bulletin Board: BKYI), ... identification solutions, today announced that it,has been awarded ... with a large multi-national technology company. BIO-key will,license ... be used on,multiple, large international and domestic opportunities., ...
... WI, JUNE 2, 2008-- An understanding how environmental ... transport and fate of agricultural chemicals in the ... degradation of surface and ground waters from past, ... has been conducted at field or smaller scales, ...
Cached Biology News:BIO-key(R) Awarded $2 Million Biometric Contract by Multi-National Company 2Holistic understanding: Ag chemicals in the environment 2
Intestinal Epithelium Differentiation Environment...
...
The Programmable MP-5000P-F Power Supply can be applied for any Microfluidic application....
... Drummond Scientific has a long and ... microinjection apparatus. Several years ago we ... displacement microdispenser was being modified to ... unit by redesigning the microdispenser to ...
Biology Products: